Market Cap (In AUD)
178.51 Million
Revenue (In AUD)
583.47 Thousand
Net Income (In AUD)
-17.07 Million
Avg. Volume
3.35 Million
- Currency
- AUD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.16-0.665
- PE
- -
- EPS
- -
- Beta Value
- 0.502
- ISIN
- AU000000DXB7
- CUSIP
- Q3191W104
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D.
- Employee Count
- -
- Website
- https://dimerix.com
- Ipo Date
- 1989-07-31
- Details
- Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.
More Stocks
-
GOSS
-
PLYFFPlayfair Mining Ltd.
PLYFF
-
SWARAJENGSwaraj Engines Limited
SWARAJENG
-
005830DB Insurance Co., Ltd.
005830
-
VCCTFVictoria PLC
VCCTF
-
KOB
-
3836
-
TTEXF